Cyanine5 amine

Cat. # Quantity Price Lead time
130C0 1 mg $110.00 in stock
230C0 5 mg $210.00 in stock
430C0 25 mg $410.00 in stock
530C0 50 mg $695.00 in stock
630C0 100 mg $1190.00 in stock

Cyanine5 amine is a reactive dye which contains amino group, an analog of Cy5® amine. This reagent can be coupled with a variety of activated esters and other electrophilic reagents. For example, this amine can be coupled with EDC-activated carboxylic groups.

This bright and photostable dye is suitable for many different methods of fluorescence detection. Colorful fluorophore can also be easily detected in small quantities (nanomols) by naked human eye.

Cyanine5 amine absorbance and emission spectra

Cyanine5 amine absorbance and emission spectra

Customers also purchased with this product

DMF (dimethylformamide), labeling grade

Dry high purity amine free solvent for NHS ester labeling.

Sulfo-Cyanine7 NHS ester

Sulfo-Cyanine7 NHS ester is a water soluble, near infrared, amine-reactive dye.

Cyanine3 carboxylic acid

Free Cyanine3 carboxylic acid.

General properties

Appearance: dark blue powder
Molecular weight: 653.77
CAS number: 1807589-58-7 (without anion), 1807529-70-9 (chloride)
Molecular formula: C38H54Cl2N4O
IUPAC name: 3H-​Indolium, 2-​[5-​[1-​[6-​[(6-​aminohexyl)​amino]​-​6-​oxohexyl]​-​1,​3-​dihydro-​3,​3-​dimethyl-​2H-​indol-​2-​ylidene]​-​1,​3-​pentadien-​1-​yl]​-​1,​3,​3-​trimethyl-
Solubility: moderate solubility in water, good in polar organic solvents (DMF, DMSO, alcohols)
Quality control: NMR 1H, HPLC-MS (95%)
Storage conditions: Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light.
MSDS: Download
Product specifications

Spectral properties

Excitation maximum, nm: 646
ε, L⋅mol−1⋅cm−1: 250000
Emission maximum, nm: 662
Fluorescence quantum yield: 0.2
CF260: 0.03
CF280: 0.04

Product citations

  1. Zhao, Y.; Fletcher, N.L.; Gemmell, A.; Houston, Z.H.; Howard, C.B.; Blakey, I.; Liu, T.; Thurecht, K.J. Investigation of the Therapeutic Potential of a Synergistic Delivery System through Dual Controlled Release of Camptothecin–Doxorubicin. Advanced Therapeutics, in press. doi: 10.1002/adtp.201900202
  2. Yamada, K.J.; Heim, C.E.; Xi, X.; Attri, K.S.; Wang, D.; Zhang, W.; Singh, P.K.; Bronich, T.K.; Kielian, T. Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance. PLoS Pathogens, 2020, 16(3), e1008354. doi: 10.1371/journal.ppat.1008354
  3. Yuan, X.; Liu, L.; Wang, W.; Gao, Y.-R.; Zhang, D.; Jia, T.-T.; Zeng, H.-R.; Pan, G.; Yuan, Y. Development of (G3-C12)-mediated camptothecin polymeric prodrug targeting to Galectin-3 receptor against androgen-independent prostate cancer. International Journal of Pharmaceutics, 2020, 580, 119123. doi: 10.1016/j.ijpharm.2020.119123
  4. Sodano, F.; Cavanagh, R.; Pearce, A.K.; Lazzarato, L.; Rolando, B.; Fraix, A.; Abelha, T.F.; Vasey, C.; Alexander, C.; Taresco, V.; Sortino, S. Enhancing Doxorubicin Anticancer Activity with a Novel Polymeric Platform Photoreleasing Nitric Oxide. Biomaterials Science, 2020, 8(5), 1329–1344. doi: 10.1039/c9bm01644a
Show more (48)
Your item has been added. View your cart or proceed to checkout
The count of items is incorrect.